Cardiac Amyloidosis: On the Road

Join us for a Cardiac Amyloidosis symposium in your region!

Cardiac Amyloidosis: Virtual On The Road in Rochester

Cardiac Amyloidosis: Virtual On the Road will convene on June 28, 2022
from 7:50 AM - 12:30 PM (US ET).

Join us for "Moving from Rarely Recognized to Rarely Missed for this Treatable Malady", chaired by Ronald G. Schwartz, MD, MASNC and Maria L. Mackin, BS, MS, CNMT, RT(N).


Free for members, $75 for non-members
Join ASNC and save on your registration!


4.5* CME/CE credits available


June 28: Moving from Rarely Recognized to Rarely Missed for this Treatable Malady
7:50 AM Introduction Ronald G. Schwartz, MD
8:00 AM My Most Interesting Cases of Cardiac Amyloidosis Hima Vidula, MD
8:30 AM New and Emerging Therapies for Cardiac Amyloidosis Jeffrey Alexis, MD
9:00 AM Dysrhythmia in Cardiac Amyloidosis: When to Call
an Electrophysiologist
Mehmet Aktas, MD
9:30 AM Serum and Urine Studies in Amyloidosis: When to Call
a Hematologist
Frank Passero, MD
10:00 AM Polyneuropathy in Amyloidosis David Herrmann, MD
10:30 AM Break  
10:45 AM Echo and MRI in the Diagnosis of Cardiac Amyloidosis Farhan Bajwa, MD
11:15 AM The Crucial Role of Technologists in a Cardiac Amyloidosis
Program: What Technologists Need to Know/Do
Maria L. Mackin, CNMT
11:30 AM Keynote: Contemporary Diagnosis and Management
of ATTR Amyloidosis With Insights From
Structure-function Relationship
Prem Soman, MD, PhD
12:15 PM Questions and Answers All Faculty
12:30 PM Adjourn  


Learning Objectives

  • How cardiac amyloidosis clinically "hides in plain sight" and what you need to do to ensure you are not missing it
  • Why the technologist's contribution is crucial to the process, and what technologists must know about cardiac amyloidosis 
  • When to call an electrophysiologist and a hematologist
  • What you, your general cardiologist and your heart failure specialist colleagues must know about
    • How cardiac amyloidosis can be diagnosed noninvasively without biopsy with high-efficiency CZT SPECT imaging
    • Emerging therapies for treatment of cardiac amyloidosis

The Cardiac Amyloidosis: On the Road programs will:

  • Address the knowledge, competence and performance gaps in disease epidemiology, pathophysiology, diagnosis and treatments for ATTR-CM. 

  • Improve diagnosis across all patient populations, timely referral to amyloid experts, and knowledge of treatment options with the goal of improving outcomes of patients with ATTR-CM. 

  • Enhance the understanding of the overlap of cardiac amyloidosis with other conditions leading to a misdiagnosis or delayed diagnosis.  

  • Focus on the diagnostic algorithm, including the appropriate use of Tc-99m PYP, and the importance of image interpretation alongside other clinical findings. 

  • Discuss the central role of Tc-99m PYP imaging and the protocols for acquisition, processing and interpretation to ensure understanding of the procedure and the data it provides.

Participants of these programs will be able to:

  • Describe amyloidosis, including specific types, cardiac features and disease burden.

  • Identify barriers to identification and diagnosis of patients suspected of ATTR.

  • Recognize patients at risk for hereditary ATTR (hATTR) and wild-type ATTR (wtATTR).

  • Summarize the diagnostic evaluation for cardiac amyloidosis including the differential diagnosis. 

  • Provide details of Tc-99m PYP including imaging protocol, semi-quantitative and quantitative scoring, interpretation including identifying false positive and false negative studies, and components of an appropriate report. 

  • Demonstrate understanding of current treatments for patients with ATTR-CM.

If you have any questions about registration, please contact

More Cardiac Amyloidosis Resources

This program is supported by an educational grant from Pfizer.

Back to top